BeiGene Stock Forecast, Price & News

+3.83 (+1.19 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume136,254 shs
Average Volume252,499 shs
Market Capitalization$29.96 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BeiGene logo

About BeiGene

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.


Form 8-K BeiGene, Ltd. For: Jun 16 -
Form 8-K BeiGene, Ltd. For: Jun 16 -
June 18, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

0.97 out of 5 stars

Medical Sector

1151st out of 2,105 stocks

Pharmaceutical Preparations Industry

527th out of 832 stocks

Analyst Opinion: 1.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BeiGene (NASDAQ:BGNE) Frequently Asked Questions

Is BeiGene a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BeiGene stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BGNE, but not buy additional shares or sell existing shares.
View analyst ratings for BeiGene
or view top-rated stocks.

What stocks does MarketBeat like better than BeiGene?

Wall Street analysts have given BeiGene a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeiGene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BeiGene

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its earnings results on Friday, May, 7th. The company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.90) by $2.59. The company earned $605.87 million during the quarter, compared to analyst estimates of $103.90 million. BeiGene had a negative net margin of 135.24% and a negative trailing twelve-month return on equity of 31.71%.
View BeiGene's earnings history

How has BeiGene's stock price been impacted by COVID-19?

BeiGene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BGNE stock has increased by 123.5% and is now trading at $325.64.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BGNE?

9 brokers have issued 12-month target prices for BeiGene's stock. Their forecasts range from $190.00 to $429.00. On average, they anticipate BeiGene's stock price to reach $334.88 in the next year. This suggests a possible upside of 2.8% from the stock's current price.
View analysts' price targets for BeiGene
or view top-rated stocks among Wall Street analysts.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, Chairman & CEO (Age 53, Pay $1.58M)
  • Dr. Xiaobin Wu Ph.D., Pres, COO & GM of China (Age 58, Pay $1.13M)
  • Dr. Xiaodong Wang, Co-Founder & Non-Exec. Director (Age 58, Pay $4M)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 58, Pay $694.61k)
  • Dr. Jane Edna Huang M.D., Chief Medical Officer of Hematology (Age 48, Pay $705.49k)
  • Mr. Daniel Maller, VP of Fin. & Accounting
  • Mr. Michael Garvey, Global Head of Technical Operations (Age 48)
  • Mr. Craig West CFA, Sr. Director of Investor Relations
  • Mr. Scott Samuels, Sr. VP & Gen. Counsel
  • Ms. Diana Lee Francis, VP and Global Head of Quality & Regulatory Compliance

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on John V. Oyler has an approval rating of 69% among BeiGene's employees.

Who are some of BeiGene's key competitors?

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital International Investors (6.32%), Baillie Gifford & Co. (4.83%), Primecap Management Co. CA (4.24%), BlackRock Inc. (2.85%), Boxer Capital LLC (0.83%) and Price T Rowe Associates Inc. MD (0.80%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene

Which major investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Sands Capital Management LLC, Price T Rowe Associates Inc. MD, Canada Pension Plan Investment Board, Barclays PLC, Bellevue Group AG, Indus Capital Partners LLC, and UBS Group AG. Company insiders that have sold BeiGene company stock in the last year include Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene
or view top insider-selling stocks.

Which major investors are buying BeiGene stock?

BGNE stock was bought by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Capital International Investors, Baillie Gifford & Co., Goldman Sachs Group Inc., New York State Common Retirement Fund, Mirae Asset Global Investments Co. Ltd., USS Investment Management Ltd, and Van ECK Associates Corp.
View insider buying and selling activity for BeiGene
or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $325.64.

How much money does BeiGene make?

BeiGene has a market capitalization of $29.96 billion and generates $308.87 million in revenue each year. The company earns $-1,596,910,000.00 in net income (profit) each year or ($19.13) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 5,300 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

What is BeiGene's official website?

The official website for BeiGene is

Where are BeiGene's headquarters?

BeiGene is headquartered at 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.